KAYLEIGH KING: Open Payments
NPI 1821219114 · IRVING, TX. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$2,737 in 95 payments from 31 companies in 2025. Trend: 2023 $247 · 2024 $3,024 · 2025 $2,737
Food & beverage: $2,039Long term medical supply or device loan: $598Education: $100
| Company | Payments | Amount |
|---|---|---|
| Novartis Pharmaceuticals Corporation | 9 | $676 |
| Daiichi Sankyo Inc. | 4 | $189 |
| Incyte Corporation | 7 | $183 |
| Janssen Biotech, Inc. | 8 | $182 |
| Celgene Corporation | 7 | $150 |
| ABBVIE INC. | 7 | $142 |
| AstraZeneca Pharmaceuticals LP | 6 | $132 |
| Merck Sharp & Dohme LLC | 5 | $116 |
| Lilly USA, LLC | 4 | $96 |
| Abbott Laboratories | 4 | $93 |
Products named: KISQALI, Enhertu, REBLOZYL, KEYTRUDA, VERZENIO, FREESTYLE LIBRE 3, AYVAKIT, VENCLEXTA.
Industry payments across TX — which companies pay providers there.
